Targeted Radionuclide Therapy in Glioblastoma,ACS Applied Materials & Interfaces

当前位置： X-MOL 学术 › ACS Appl. Mater. Interfaces › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Targeted Radionuclide Therapy in Glioblastoma
ACS Applied Materials & Interfaces ( IF 8.3 ) Pub Date : 2024-07-23 , DOI: 10.1021/acsami.4c07850
Xiaobin Zhao _{1,

2,

3,

4,

5} , Vivianne Jakobsson _{1,

2,

3,

5} , Yucen Tao _{1,

3,

5} , Tianzhi Zhao _{1,

2,

3,

5} , Jingyan Wang ₆ , Pek-Lan Khong _{1,

2} , Xiaoyuan Chen _{1,

2,

3,

5,

7,

8} , Jingjing Zhang _{1,

2,

3,

5}

Affiliation

Department of Diagnostic Radiology, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore 119074, Singapore.
Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore.
Theranostics Center of Excellence, Yong Loo Lin School of Medicine, National University of Singapore, 11 Biopolis Way, Helios, Singapore 138667, Singapore.
Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.
Xiamen University, School of Public Health, Xiang'an South Road, Xiamen 361102, China.
Departments of Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore 119074, Singapore.
Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore 138673, Singapore.

Despite the development of various novel therapies, glioblastoma (GBM) remains a devastating disease, with a median survival of less than 15 months. Recently, targeted radionuclide therapy has shown significant progress in treating solid tumors, with the approval of Lutathera for neuroendocrine tumors and Pluvicto for prostate cancer by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This achievement has shed light on the potential of targeted radionuclide therapy for other solid tumors, including GBM. This review presents the current status of targeted radionuclide therapy in GBM, highlighting the commonly used therapeutic radionuclides emitting alpha, beta particles, and Auger electrons that could induce potent molecular and cellular damage to treat GBM. We then explore a range of targeting vectors, including small molecules, peptides, and antibodies, which selectively target antigen-expressing tumor cells with minimal or no binding to healthy tissues. Considering that radiopharmaceuticals for GBM are often administered locoregionally to bypass the blood-brain barrier (BBB), we review prominent delivery methods such as convection-enhanced delivery, local implantation, and stereotactic injections. Finally, we address the challenges of this therapeutic approach for GBM and propose potential solutions.

中文翻译：

胶质母细胞瘤的靶向放射性核素治疗

尽管开发了各种新疗法，胶质母细胞瘤 (GBM) 仍然是一种毁灭性的疾病，中位生存期不到 15 个月。最近，靶向放射性核素治疗在治疗实体瘤方面取得了重大进展，美国食品和药物管理局（FDA）和欧洲药品管理局（EMA）批准了用于治疗神经内分泌肿瘤的Lutathera和用于治疗前列腺癌的Pluvicto。这一成就揭示了靶向放射性核素治疗其他实体瘤（包括 GBM）的潜力。本综述介绍了 GBM 靶向放射性核素治疗的现状，重点介绍了发射 α、β 粒子和俄歇电子的常用治疗性放射性核素，这些放射性核素可以诱导有效的分子和细胞损伤来治疗 GBM。然后，我们探索了一系列靶向载体，包括小分子、肽和抗体，它们选择性地靶向表达抗原的肿瘤细胞，而与健康组织的结合很少或不结合。考虑到 GBM 放射性药物通常局部给药以绕过血脑屏障 (BBB)，我们回顾了主要的递送方法，如对流增强递送、局部植入和立体定向注射。最后，我们解决了这种 GBM 治疗方法的挑战并提出了潜在的解决方案。

更新日期：2024-07-23

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南